UK markets closed

Insmed Incorporated (0JAV.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
19.78+1.13 (+6.06%)
At close: 07:11PM GMT

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900

Full-time employees613

Key executives

NameTitlePayExercisedYear born
Mr. William H. Lewis J.D., M.B.A.Pres, CEO & Chairman1.32M5.32M1969
Ms. Sara M. Bonstein MBAChief Financial Officer702.22kN/A1981
Mr. Roger AdsettChief Operating Officer871.13kN/A1969
Ms. S. Nicole SchaefferChief People Strategy Officer660.81k1.18M1968
Dr. Martina Flammer M.B.A., M.D.Chief Medical Officer787.6kN/A1964
Mr. John Goll IIISr. VP & Chief Accounting OfficerN/AN/AN/A
Eleanor BarisserAssociate Director of Investor RelationsN/AN/AN/A
Mr. Michael Alexander SmithSr. VP & Gen. CounselN/AN/A1978
Mandy FaheyExec. Director of Corp. CommunicationsN/AN/AN/A
Mr. John Drayton WiseSr. VP, Head of United States & Chief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate governance

Insmed Incorporated’s ISS governance QualityScore as of 28 November 2022 is 5. The pillar scores are Audit: 6; Board: 2; Shareholder rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.